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unduly, for they keep boredom at bay, and spark creativity” 
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ABSTRACT	  
 
Novel molecular tools for infectious disease diagnostics are constantly under 
development to reduce the time between onset of symptoms and diagnosis. Not 
only is it important to receive appropriate treatment, but also to avoid 
unnecessary use of antibiotics. The availability of rapid diagnostics is also 
important when epidemics or pandemics emerge. The purpose of this project was 
to examine the applicability of Förster resonance energy transfer (FRET) in 
homogeneous immunoassays, and to develop new diagnostic approaches. FRET 
has widely been applied in proximity-based assays, such as those measuring 
antigen-antibody binding. In FRET, energy is transferred between two 
chromophores, the donor and the acceptor, when in close proximity. Utilizing 
FRET as detection method for immunoassays enables the development of wash-
free (homogeneous) simple workflow assays. In this thesis, of the three FRET-
based rapid immunoassays that were set up, two served in clinical diagnosis. 
Study I (I) examined the possibility of detecting antibodies by FRET-pair forming 
fluorophore-labeled antigens, which upon binding to an antibody would induce a 
FRET signal. This homogeneous immunoassay, designated FRET-bridge, was 
successfully optimized for streptavidin (SA). By combining donor-labeled and 
acceptor-labeled SAs with anti-SA antibodies, FRET signals were recorded with 
high signal-to-noise ratios. When molecular determinants behind the FRET 
signals were examined, most of the FRET activity originated from fairly large 
immunocomplexes rather than from one IgG and two antigens. At the moment, 
SA represents the only antigen fully functioning in the FRET-bridge assay. This is 
most likely due to the multivalent nature of the antigen, which seems beneficial in 
FRET signal formation.  
Next, we introduced another homogeneous immunoassay (II), the LFRET assay. 
Here, a FRET pair forming fluorophore-labeled antigen and fluorophore-labeled 
protein L induce a signal if bound to the Fab (fragment antigen-binding) region of 
an immunoglobulin. To demonstrate the usefulness of the assay, SA served as 
test antigen. The assay was next optimized for virus diagnostics by use of 
Puumala virus (PUUV) nucleocapsid protein as antigen (III). In all, 211 serum 
samples underwent examination by the LFRET assay, representing acute (n=61) 
or past PUUV infection (n=27), and seronegative (n=123) individuals. With a 
ABSTRACT 
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simple workflow and an assay time of 30 minutes, the LFRET assay, compared 
to the reference tests, identified acute PUUV infection at 100% specificity and 
95% sensitivity. 
The fourth study (IV) involved a competitive homogeneous immunoassay for the 
detection of PUUV antibodies from clinical samples. This assay, CFRET, is 
based on competition between fluorophore-labeled monoclonal antibodies 
(MAbs) and serum antibodies. Here, a donor-labeled antigen and an acceptor-
labeled MAb form the FRET pair. If the clinical sample contains antibodies 
against the labeled antigen, they compete with the MAb for antigen binding, 
resulting in FRET signal decrease. Analysis of assay performance included a 
panel of 329 samples representing acute (n=101) or past (n=42) infection, and 
negative samples (n=186). The one-step CFRET assay performed at 99% 
specificity and 100% sensitivity in diagnosis of hantavirus disease compared to 
the reference tests, and with a rapid assay time of 30 minutes. 
The three rapid diagnostic approaches introduced herein represent simplicity, 
and show that diagnostics need not be time-consuming. Although the assays 
were optimized for accurate diagnosis of acute infection, both assays also 
recognized life-long immunity, albeit with lower sensitivity. By optimization, the 
assays could be developed towards more sensitive detection of past infection as 
well. The LFRET and CFRET assays thus represent innovative tools for rapid 
antibody detection, and their potential in serodiagnosis of diverse microbial 
infections and possibly even in detection of auto- and anti-allergen antibodies 
calls for further exploration.    
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TIIVISTELMÄ	  
 
Tartuntatautien diagnostiikkaan kehitetään jatkuvasti uusia pikatestejä, jotta 
diagnoosi saataisiin mahdollisimman nopeasti oireiden ilmaannuttua. Nopea 
diagnoosi varmistaa sen, että oikea hoito voidaan aloittaa mahdollisimman pian, 
ja samalla vältytään turhilta antibiooteilta. Diagnostiset pikatestit ovat myös 
tärkeitä epidemioiden tai pandemioiden hallinnassa. Tämän projektin 
tarkoituksena oli hyödyntää Förster resonance energy transfer (FRET) ilmiötä 
homogeenisten vasta-ainetestien kehittämisessä. Tutkimuksen tuloksena 
pystytettiin kolme erityyppistä vasta-ainetestiä, joista kahta sovellettiin kliiniseen 
diagnostiikkaan. 
Ensimmäisessä osajulkaisussa (I) tutkittiin, voisiko vasta-aineita tunnistaa 
sellaisten fluorofori-leimattujen antigeenien avulla, jotka yhteen liittyessään 
muodostaisivat FRET-parin. Tutkimusasetelma perustui oletukseen, jonka 
mukaan näiden fluorofori-leimattujen antigeenien sitoutuessa samaan vasta-
aineeseen, muodostuu FRET-signaali. Tämä testi, FRET-bridge, kehitettiin alun 
perin streptavidiini (SA) -malliantigeenille. FRET-signaali muodostui, kun 
luovuttaja- ja vastaanottajafluoroforileimatut SA:t yhdistyivät SA-vasta-aineiden 
toimesta. Työssä tutkittiin muodostuvia FRET-signaaleja molekyylitasolla ja 
huomattiin, että suurin osa signaaleista oli peräisin isoista 
immuunikomplekseista, eikä niinkään kahdesta antigeenista ja yhdestä vasta-
aineesta. Toistaiseksi SA on ainoa antigeeni, joka tässä testissä toimii kunnolla. 
Tämä johtuu todennäköisesti SA:n multivalentista luonteesta, mikä vaikuttaisi 
edistävän FRET-signaalin muodostusta. 
Toisessa ja kolmannessa osajulkaisussa (II, III) tutkittiin homogeenisen vasta-
ainetestin soveltuvuutta tartuntatautien diagnostiikkaan. Kyseinen testi, nimeltään 
LFRET, perustuu fluoroforileimatun antigeenin sekä fluoroforileimatun proteiini 
L:n interaktioon niiden sitoutuessa saman vasta-aineen Fab (fragment antigen-
binding) -osaan. Myös tämä testi optimoitiin käyttäen SA:ia, jonka jälkeen 
ensimmäisenä virusantigeenina käytettiin Puumala-viruksen (PUUV) 
nukleokapsidiproteiinia. Työssä testattiin kaikkiaan 211 seeruminäytettä, jotka 
edustivat akuuttia vaihetta (n=61), vanhaa immuniteettia (n=27) ja PUUV:lle 
negatiivisia näytteitä (n=123). LFRET-testi tunnisti akuuttia myyräkuumetta 100% 
tarkkuudella ja 95% herkkyydellä verrattuna referenssitestien tuloksiin. 
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Neljännessä osajulkaisussa (IV) pystytettiin kilpaileva homogeeninen vasta-
ainetesti nimeltään CFRET. Tämä testi perustuu kilpailuun antigeeniin 
sitoutumisesta fluoroforileimatun monoklonaalisen vasta-aineen (MAb) ja 
seerumin vasta-aineiden välillä. Tässä testissä MAb sekä antigeeni muodostavat 
FRET-parin. Jos seeruminäyte sisältää vasta-aineita, jotka sitovat kyseistä 
antigeenia, syntyy kilpailutilanne vasta-aineiden välille, mikä puolestaan johtaa 
FRET-signaalin laskuun. Työssä testattiin yhteensä 329 näytettä, jotka edustivat 
akuuttia vaihetta (n=101), vanhaa immuniteettia (n=42) ja PUUV:lle negatiivisia 
näytteitä (n=186).  CFRET tunnisti akuuttia myyräkuumetta 99% tarkkuudella ja 
100% herkkyydellä verrattuna referenssitestien tuloksiin. 
Edellä kuvatut kolme pikatestiä ovat yksinkertaisia ja ne todistavat, että 
diagnostisen testin ei tarvitse olla aikaavievä. Vaikka sekä LFRET- että CFRET-
testi kehitettiin tunnistamaan akuuttia infektiota, molemmat testit tunnistivat myös 
vanhaa immuniteettia, joskaan ei yhtä herkästi kuin akuuttia infektiota. 
Hienosäädön myötä on mahdollista, että kyseistä ominaisuutta voitaisiin parantaa 
entistä herkemmäksi. LFRET- ja CFRET-testit tarjoavat uraauurtavia 
mahdollisuuksia vasta-aineiden pikadiagnostiikkaan, ja niiden soveltuvuutta 
useiden eri taudinaiheuttajien diagnostiikkaan sekä auto- että anti-allergeeni 
vasta-aineiden tunnistamiseen tulisi tutkia lisää. 
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FOREWORD	  
 
Infectious diseases have greatly influenced the history of mankind. One of the 
most lethal pandemics took place in the 14th century, the Black Death (the 
plague, caused by Yersinia pestis), resulting in the death of an estimated 75 to 
200 million people. Another devastating example of deadly pandemics was the 
Spanish flu caused by the influenza A virus in the 1918, causing 20 to 40 million 
deaths. Both pandemics occurred in an era when no proper diagnostics or cure 
existed.  
Today, a variety of infectious diseases are ”under control” due to national 
vaccination programs. However, the emergence and re-emergence of pathogens, 
most often viruses, is continuous. Globalization, urbanization, environmental 
changes, and increased travel facilitate the rapid spread of highly contagious 
pathogens. The role of diagnostics in the battle against novel and re-emerging 
diseases is crucial. In fact, the development of diagnostics is one of the first 
reactions to any novel pathogen.     
The first part of the literature review focuses on diagnostics with emphasis on 
immunology and serodiagnostics. After review of the basics of established 
diagnostics, ranging from nucleic-acid detection to immunoassays, comes 
presentation of the concept of rapid diagnostic tests (RDTs). The general reason 
for RDTs is to shorten the time for accurate diagnosis, and also to reduce labor 
and possibly even assay costs. In addition, such tests can be utilized in resource-
limited conditions such as field laboratories and in developing countries at the 
point of care.  
The last section of the literature review deals with luminescence and applications 
based on this phenomenon. Luminescence is light emitted by a substance, and 
can be produced in several ways. This section also provides a detailed 
description of a photoluminescent phenomenon called Förster resonance energy 
transfer (FRET). FRET has proven specifically useful in proximity-based assays 
such as those detecting antibody-antigen interaction.       
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LITERATURE	  REVIEW	  
 
Diagnosis of microbial infections  
The vast majority of methods for microbiological diagnostics rely on the following 
procedures: microbial culture, morphological identification of the pathogen, 
detection of nucleic acids, or detection of antigens or specific antibodies. Bacteria 
are often cultivated on selective plates followed by their morphological and 
biochemical identification. Numerous methods exist for detection of the microbial 
genome, which are based on the specific knowledge of the nucleic acid 
composition. Rapid methods often rely on detection of the surface antigen(s) of a 
pathogen, whereas serodiagnostic methods measure specific antibodies 
developed against a pathogen. The choice of the method used depends much on 
the patient´s symptoms, medical history, travel history, and especially on 
characteristics of the suspected pathogen. The first task is to distinguish whether 
the pathogen is a bacterium, a virus, a fungus, or a parasite. One of the routine 
actions is to take a blood sample from the patient. In the case of a bacterial 
infection, the white blood cell count may be elevated. Another indication of a 
bacterial infection may be the abundance of blood C-reactive protein (CRP) 
(5,50). This literature review focuses on methods for bacterial and viral 
diagnostics, with emphasis on serodiagnostics and viral infections. 
Immunity	  and	  infectious	  diseases	  
In human beings, the immune system is divided into innate and adaptive 
systems. The innate immune system plays the central role in generic responses 
to pathogens, whereas the adaptive immune system is responsible for more 
specific immune responses such as the production of antibodies against a given 
pathogen and immunological memory. Innate immunity is normally short-lived, 
whereas the adaptive immune state may last for a lifetime. The innate immune 
system has several functions. These include activation of the complement system 
by the pathogen or its fragments, which may directly kill the pathogen or activates 
other immune mediators to the site of infection, or both. White blood cells 
(leukocytes), such as natural killer cells, macrophages, and dendritic cells, play a 
major role in killing the pathogen and evoking adaptive immune responses.  
LITERATURE REVIEW 
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The innate immune system activates the adaptive immune system through a 
process called antigen presentation. In the early stage of infection, macrophage 
and dendritic cells of the innate immune system recognize the foreign material, 
engulf it and present peptide fragments of the invader on the cell surface as part 
of the machinery called the major histocompatibility complex (MHC). This process 
is called “antigen presentation.” Peptides are recognized by the T cells of the 
adaptive immune system, which initiates the process for differentiation into active 
defence cells and production of inflammatory mediators. This process includes 
the activation and maturation of antibody-producing B cells. Differentiated B cells 
called plasma cells produce antibodies against foreign material, such as a virus, 
an action that helps to eliminate the pathogen. A fraction of these mature B cells 
also remain as memory cells to develop immunological memory (95).    
Immunoglobulins	  	  
Immunoglobulin (Ig) is a multimeric glycoprotein produced by the plasma cells of 
the adaptive system. Immunoglobulins are produced in soluble form, which are 
secreted from the cell, and also in membrane-bound forms attached to the cell 
surface. The membrane-bound Igs are referred to as B cell receptors (BCRs), 
whereas the soluble forms are called antibodies (95). 
Depictions of the basic structure of human IgGs are often Y-shaped, even 
though, according to the structural studies, the structure is actually somewhere 
between a T- and Y-shape (Figure 1) (123). This includes four polypeptide chains 
in which two identical heavy (H) and light (L) chains are linked by disulphide 
bonds. These L chains exist in two forms: kappa (κ) and lambda (λ). The heavy 
and light chains are synthesized separately and thereafter united to form two H 
and L chain (HL chain) pairs, both being able to bind one antigen molecule. Thus, 
given the bivalent nature of immunoglobulin, one Y-shaped immunoglobulin can 
simultaneously bind two antigens (92). 
The Y-shaped immunoglobulin molecule, roughly 150 kDa in size, can be divided 
into several fragments. For example, an immunoglobulin treated with papain 
yields three fragments: two Fab fragments and one Fc (fragment crystallizable) 
fragment. The papain cleavage site is located in the hinge-region. The Fc 
fragment contains domains of the H chains, whereas the Fab fragment contains 
domains of both H and L chains, and mediates the antigen recognition. The Fab 
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regions include both variable (V) and constant (C) domains, whereas the Fc 
region includes only C domains. The antigen-binding sites of an immunoglobulin 
locate at the tips of the Fab fragments, which consist of variable H- and L-chain 
domains. These sites are highly specific for each antigen (88,110). The Fc region 
interacts with cell surface receptors called Fc receptors, and also with the 
complement system, thus activating the adaptive immune system (95). 
 
 
 
 
 
 
 
 
Figure 1. Schematic structure of an immunoglobulin molecule. Variable regions of 
the H and L chain are in light blue. 
Based on differences in the structure of the H chain, immunoglobulins are divided 
into five classes: IgG, IgM, IgA, IgE, and IgD. The amount of the basic Y structure 
of Ig varies between the five classes. IgG, IgE, and IgD exist as monomers, 
whereas IgA exists usually as a monomer (in serum) or dimer (in secretions), and 
IgM mostly as a pentamer (4,110). In serum, the predominant immunoglobulins 
are those of the IgG class, whereas the IgM-class immunoglobulins are abundant 
only during infections. The IgA-class immunoglobulins are found in external 
sections such as tears, milk, saliva, and in the gut, and they play a role in 
mucosal immunity. The-IgE class immunoglobulins are mainly associated with 
allergies, whereas the function of IgD is to stimulate B cells and antimicrobial 
actions through interactions with basophils and mast cells (20,92). 
The IgG and IgA classes are further divided into subclasses that vary in their H-
chain physico-chemical, antigenic, and biologic properties. The IgG subclasses 
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include IgG1-IgG4, whereas the IgA class has only two subclasses: IgA1 and 
IgA2. The four IgG subclasses differ in their C domain, particularly in the hinge 
regions and upper CH2 domains, and are highly conserved. These regions are 
responsible for effector functions of antibodies, since they contain binding sites to 
both IgG-Fc receptors (FcγR) and C1q (complement). Hence, the effector 
functions of IgG subclasses differ in terms of triggering FcγR-expressing cells 
and complement activation. Each subclass also exhibits a unique profile 
regarding antigen binding, immune-complex formation, half-life, and placental 
transportation.  
In addition, the subclasses vary in their abundance in serum, IgG1 being the 
most abundant, followed by IgG2, IgG3, and IgG4 in decreasing order (131). Of 
the IgA subclasses, IgA1 is more abundant in serum, whereas IgA2 
predominates in secretions such as milk and saliva (26). The L chain types (κ and 
λ) can also serve to classify immunoglobulins, and hence the subclasses can be 
further divided into IgG1-4, κ and IgG1-4, λ (92). Immunoglobulins can also be 
classified according to their V gene segments. Both heavy and light chains have 
their own V segments (VH and VL, respectively), and the VH and VL segments can 
be further divided into families based on sequence and structural similarity (110). 
Immunoglobulin	  binding	  molecules	  
The target molecules that immunoglobulins bind are designated as antigens. The 
soluble immunoglobulins (i.e. antibodies) can recognize almost any type of 
biological material as an antigen, including hormones, lipids, sugars, 
carbohydrates, phospholipids, nucleic acids, and proteins. The parts of an 
antigen that immunoglobulins recognize are called epitopes. One antigen can 
contain several epitopes, but each Fab arm of an immunoglobulin binds only to a 
single epitope. Epitopes formed by several adjacent amino acid residues are 
called linear epitopes. These epitopes are often inaccessible within the native 
form of the antigen, and become accessible when the antigen is denatured. 
Conformation epitopes, in contrast, form in areas where the residues are in 
juxtaposition, not due to their proximity in the amino acid sequence, but due to 
the protein folding. This antigen-antibody binding can be highly specific, but 
cross-reactions may occur, for example, if two antigens show marked similarity in 
their structure (2). Microbial proteins, or respective recombinant expression 
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products, serve in diagnostics as antigens to detect microbe-specific antibodies 
(102). The interaction of antigen and antibody is noncovalent and reversible (2). 
Several immunoglobulin-binding proteins commonly serve to immobilize, detect, 
or purify immunoglobulins. Most were originally identified in bacteria, and 
thereafter produced as recombinant proteins. These microbial superantigens 
function to activate T-cells, and their properties differ in terms of the binding site 
in Ig and their ability to bind different Ig subclasses. The most commonly used 
are protein G, protein A, protein A/G, and protein L. Protein A is derived from 
Staphylococcus aureus (43,83), and has a binding site in the Fc region of an 
immunoglobulin, whereas Protein G originates from group C and G Streptococcal 
bacteria, and binds both Fc and Fab regions (36,117). Protein A and G both show 
strong affinity towards human IgG-class Igs. A chimeric form (protein A/G) also 
combining the IgG-binding domains of both Protein A and Protein G has been 
generated (30). Protein L derives from Finegoldia magna and has a binding site 
in the Fab region of an Ig. Protein L binds the human κ L chain without interfering 
with antigen recognition (3), and is capable of binding all Ig classes (IgG, IgM, 
IgA, IgE, and IgD) (24). Of the four major VLκ (I-VI) subgroups, only those from 
VLκII were unable to bind protein L (97,98,137). Additionally, protein L binds to 
single-chain variable fragments (scFv) and to Fab fragments bearing κ L chains. 
Hence, protein L binds to a wider range of Ig classes and subclasses than do the 
other Ig-binding proteins described here (11,97).  
Immunoassays	  
Immunoassays in general rely on the ability of an antibody to identify and bind a 
specific macromolecule that is referred to as an antigen. Depending on the assay 
type, the analyte detected can be either an antibody or an antigen. Solomon 
Berson and Rosalyn Yalow introduced the first immunoassay techniques in the 
1950s and 1960s (8,139). During the first decades, the immunoassays were 
mostly performed by means of radioactive labels. Since these labels were not 
considered the safest choice, scientists started developing novel approaches 
based on other reporter techniques (78).  
The first descriptions of immunoassays using enzyme labels appeared in the 
1970s, and are referred to as enzyme-immunoassay (EIA) or enzyme-linked 
immunosorbent assay (ELISA) (32,128). Ever since, ELISA-based applications 
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have played an important role in experimental research, veterinary medicine, 
clinical laboratories, and agriculture (33,78). Other clinically important 
immunoassays include IFA, immunoblotting, and immunochromatography. Basic 
characteristics of these assays are in Table 1 (41,63,86,101).  
Immunoassays in general can be classified into heterogeneous and 
homogeneous, and competitive or non-competitive. Heterogeneous assays 
include various steps such as incubations and washings, whereas homogeneous 
assays are wash-free, and thus easier and more rapid to perform. In a 
competitive format, labeled and non-labeled analytes compete in binding of an 
antibody or antigen, and the signal detected inversely correlates with the amount 
of the analyte. In the non-competitive formats, such as in many ELISAs, the 
signal measured is proportional to the amount of analyte (23).  
 
Table 1. Clinically important immunoassays. The basic characteristics of IFA, 
immunoblotting, immunochromatography, and ELISA with examples of sample material, 
assay time, and main benefits of each assay. 
 
Immunoassay Specimen 
Assay 
time Benefits 
IFA 
serum, 
tissue 2-3 h 
staining pattern visible in the cell (morphological 
identification), quantitative 
Immunoblotting 
serum, 
tissue 5-8 h 
 
sensitive, simultaneous detecion of antibodies 
against several antigens 
Immunochromatography 
serum, 
blood, urine 5-15 min 
 
rapid (point-of-care), simple 
 
ELISA serum, 3-4h quantitative, sensitive, high throughput format 
 
Bacterial	  infections	  
Gram staining is a method classifying bacteria into either Gram-positive or Gram-
negative; it often serves as the initial diagnostic method. Gram staining 
differentiates bacterial species into two groups by the composition of their cell 
walls.  Microscopy, with or without staining, enables the identification of several 
bacterial infections, but morphological identification is always accompanied by 
other diagnostic procedures (9,15). By culturing the bacteria, specific features of 
the bacterial species, such as growth temperature, culture media, susceptibility to 
antibiotics, metabolic properties, and oxygen requirement (aerobic vs. anaerobic) 
emerge that are useful in identification. After primary classification as Gram-
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positive or -negative, bacterial identification normally utilizes enzymatic and other 
assays (5).  
Antigen detection, although uncommon in bacterial diagnostics, also serves as a 
method for identification of certain bacterial infections. For example, several of 
the rapid tests available for group A streptococcal infection are based on antigen 
detection (79,121). Another important and increasingly popular method in specific 
detection of bacterial types is nucleic acid detection, such as the polymerase 
chain reaction (PCR) (115). Serological diagnosis of bacterial infections is 
relatively rare, but is commonly employed in certain cases, when the culture 
method is not optimal for diagnostics. Serological approaches are applied in 
diagnosis of, for example, Borrelia spp. (21,100). 
Viral	  infections	  
The most common methods in virus diagnostics include detection of the virus 
itself by virus culture or electron microscopy, detection of antibodies developed 
against the virus in the host, and detection of fragments of the virus such as the 
viral genome or proteins (antigens). Growing the virus in cell culture allows 
specific features such as the host-cell specificity and morphological changes 
caused in the infected cell to be identifiable. The role of viral culture is, however, 
diminishing. Antigen detection is particularly useful for viruses that are difficult to 
cultivate, or that grow slowly. The advantages of antigen detection include rapid 
assay time and sample handling, since the virus needs not to be viable in the 
sample. Fluorescence antibody staining (FA), EIA, and immunoperoxidase 
staining (IP) are common methods of viral antigen detection (70,122). 
The virus can also be identified by nucleic acid detection (or testing, NAT), a 
highly sensitive diagnostic method. NAT relies on amplification of the viral DNA or 
RNA, such as by PCR, much as in bacterial diagnostics. PCR use requires prior 
knowledge of the pathogen´s genome, and the design of specific primers(86). In 
addition to PCR, in clinical virology, serology (i.e. detection of antibodies) is 
common (122). 
Serodiagnosis	  	  
Serodiagnosis of viral infections is classically based on the detection of 
immunoglobulin G (IgG)- and immunoglobulin M (IgM)-class antibodies. 
Serological approaches are especially useful for viruses difficult to culture, such 
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as the human immunodeficiency virus (HIV) or the Epstein-Barr virus (EBV) 
(5,25,39). The disadvantage of serology is the usual lag between onset of acute 
symptoms of infection and antibody formation, making it a rather slow method. In 
most cases, an acute infection is diagnosed by the presence of IgM or rising IgG 
titers between the acute and convalescent phase of infection (Figure 2) (5). In 
certain infections such as rubella, and conditions such as pregnancy, IgM 
detection is insufficiently accurate, and serodiagnosis should be based not solely 
on IgM detection. If such an infection is suspected, performance of serodiagnosis 
can be based on IgG avidity (functional affinity) (60,106). IgG avidity refers to the 
overall strength of the antigen-antibody interaction, the strength of which matures 
over time, meaning that low IgG avidity is an indicator of primary infection, 
whereas high IgG avidity suggests past infection (48,77,104). IgG avidity has 
been applicable to the diagnosis of rubella, PUUV, hepatitis virus, human herpes 
viruses, HIV, and parvovirus B19, to name a few (19,31,42,49,104,124).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Infection- and antibody-response kinetics. At the onset of primary infection, 
the IgM response is usually formed within days of the exposure, after which the IgG 
molecules begin to form. IgG avidity matures during the first 6 months. Modified with the 
permission of the creater of the figure, Aftab Jasir (66). 
 
Usually past-infection antibodies (IgG) are detectable even years after infection, 
and many viral infections provide life-long immunity (95). Unfortunately, some 
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viruses, ones such as influenza A, show such high genetic variation that acquired 
immunity against a certain virus strain does not necessarily protect against other 
strains (14,105). The presence of IgG-class antibodies, and the lack of IgM, is 
usually an indication of past infection. In some cases, the early IgG response is 
against epitopes or antigens differing from those involved in the late IgG 
response (67).  
Diagnosis	  of	  Puumala	  virus	  infection	  
Puumala virus (PUUV, genus Hantavirus, family Bunyaviridae), a zoonotic virus 
carried by chronically infected bank voles (Myodes glareolus), is endemic in 
Finland. Human infection by PUUV is most commonly acquired via inhalation of 
aerosolized rodent excreta and manifests as a disease called nephropathia 
epidemica (NE) (35,130).  
Typical symptoms of NE include abrupt fever, followed by headache, nausea, 
vomiting, abdominal pain, and signs of renal insufficiency. Somnolence and 
visual disturbances as well as pulmonary, cardiac, and central nervous system 
symptoms are also common (73,113,114,130). In acute-phase PUUV infection, 
the IgG antibodies are mainly targeted to the viral nucleocapsid (N) protein, 
whereas in its later stages, IgG antibodies against the glycoproteins Gc and Gn 
become more prominent (130). The N protein exists as monomeric, dimeric, and 
trimeric forms; the first two are transient, and the trimeric is the most stable form 
(93). Laboratory diagnosis of PUUV infection is based on detection of 
immunoglobulins (IgM and IgG), i.e. serodiagnostics. Antibody detection is 
commonly based on EIA, immunochromatography (IgM), immunoblotting using 
recombinant PUUV N as antigen, or an immunofluorescence assay (IFA) based 
on acetone-fixed infected cells (49,63,67). 
Next-­‐generation	  diagnostics	  
In addition to the classical methods, a number of new diagnostic tools exist. 
These new technologies offer great advantages, such as rapid assay time, 
multiplexing (simultaneous detection of several pathogens in a single assay), 
portable devices (enabling use in resource-limited settings), automation, and one-
step workflows—advantages that the classical methods lack (15). 
The platform design of microarrays, for example, enables high-throughput 
screening and multiplexing (16,81). Microarrays have been applied to a variety of 
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analytes. DNA microarray-based commercial products are available, for example, 
for diagnosis of sepsis (125) or of human herpesviruses(64). As an example, one 
commercial DNA-based microarray simultaneously identifies 50 different bacterial 
species or taxons as well as one antibiotic-resistance gene. The procedure is 
simple: after extraction of the DNA from blood culture, followed by (multiplex) 
PCR amplification, the products are hybridized on a microarray, and the results 
detected with specific software (125). Other examples of popular microarray 
applications include those detecting peptides and proteins (65,132). 
Another example of a modern diagnostic method is mass spectrometry (MS). 
MALDI-TOF (Matrix-Assisted Laser Desorption Ionization Time-Of-Flight) -based 
MS methods have proven useful specifically for identifying difficult-to-cultivate 
bacteria (10). The method itself is not new, but the applications for microbial 
diagnostics are (17,87). Mass spectrometry allows for assessment of the 
chemical composition of a sample by detection of the mass-to-charge ratio of a 
bioanalyte. The resultant mass-spectral fingerprint of sample is thereafter 
compared to a database of known pathogens. The MS-based applications 
provide interesting alternatives for conventional diagnostics, with certain benefits 
such as rapid assay time, cost-efficiency, and the ability to analyze all pathogens 
present in a sample during a single assay (87). This method, however, relies on 
an up-to-date protein-fragment database that requires constant updating; this 
makes the user dependent on the manufacturer. 
Employment of next-generation sequencing (NGS) in infectious disease 
diagnostics is expanding. The traditional PCRs are based on specific primers, 
and hence are able to identify only the targeted microbe; in many cases the 
method is unable to discriminate between genotypes, since the primers are 
targeted on conserved genomic areas. Moreover, several tests need to be 
conducted if the first etiological hypothesis proves incorrect. The advantages of 
applying NGS in clinical diagnostics is that it does not require specific primers, 
and only one assay provides information on all pathogenic DNA or RNA present 
in the sample. Further development is required in terms of sample preparation, 
availability of the sequencer in central laboratories, of bioinformatics, and of 
costs, before NGS could become routine practice in diagnostics (76). Scientists 
anticipate that NGS technology will prove particularly useful in identifying novel 
pathogens (6). 
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Rapid	  diagnostics	  	  
Rapid and accurate treatment calls for rapid and specific diagnostics, which is 
often useful to prevent misuse of antibiotics. Over the years, researchers have 
developed rapid diagnostic tests (RDTs) for a variety of disease conditions. The 
motivation to develop such tests is to shorten the turnaround time, as well as the 
ability to use these in resource-limited settings such as in the developing world at 
the point of care (29,47,61,85,103). Rapid diagnostics also plays an important 
role during epidemics and pandemics. One estimation is that availability of RDTs 
during recent West African Ebola epidemics would have reduced the scale of the 
epidemics by over a third, if primary tests (RDTs) had been used in combination 
with a confirmatory PCR (99).  
Many RDTs are also point-of-care (POC) tests. Among several ways to define the 
term POC test is as ”a medical test conducted at or near the site of patient care” 
(29). The first POC test was developed in 1962 for measuring blood glucose (22). 
The next breakthrough in this field was the development of a rapid pregnancy test 
in 1977 (1). During the past decades, POC-test availability has been expanding 
rapidly, also for infectious disease diagnostics. POC testing has demonstrated 
effective sampling and diagnostic testing in resource-limited settings. Simple 
POC assays require only minimal personnel training, but interpretation of test 
results requires a health-care professional, who may or may not be on site. The 
characteristics of an ideal POC assay include accuracy (sensitivity and 
specificity), heat-stable reagents, portability, minimal user-training requirements, 
rapidity (assay time of 1-2 hours), cost efficiency, and suitability for a number of 
clinical specimens. In resource-limited locations, diagnostic assays should 
require little or no power input, and minimal training requirements for both 
operation and interpretation of test results. Any need for cold-chain (storage of 
samples or reagents) should also be minimal (15). Several rapid assays are 
available for infectious diseases, including HIV, influenza A and B, group-A 
streptococcal infection, syphilis, and malaria. Many of these tests, however, 
suffer from poor sensitivity and specificity (15,103,122).  
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Luminescence 
Luminescence is light emitted from certain materials at relatively low 
temperatures, such as room temperature. In luminescence, an energy source 
triggers a sequence of events, in which an electron enters into an excited state 
and dissipates its energy by emitting light at certain (usually lower) wavelengths. 
Luminescence can be formed in several ways, depending upon its energy source 
(127). Luminescence types are described in Table 2, but it should be noted that 
several classification patterns exist in the literature, of which this table represents 
only one (126). 
 
Table 2. Luminence types and their energy sources. 
 
Type of Luminescence Energy source 
Chemiluminescence Chemical reaction 
Electroluminescence Electric field 
Cathodoluminescence Cathode rays 
Triboluminescence Frictional and electrostatic forces  
Bioluminescence In vivo biochemical reaction 
Sonoluminescence Ultrasound 
Photoluminescence Absorption of light (photons) 
    Fluorescence  
    Phosphorescence  
Radioluminescence Ionizing radiation 
Thermoluminescence Heating after prior storage of energy 
 
Photoluminescence is the form of luminescence in which radiation serves as the 
energy source, and absorption of photons produces emission of light (127). One 
specific type of photoluminescence, fluorescence, has been employed in a 
variety of immunodiagnostic tools. One luminescence-based phenomenon is 
called Förster resonance energy transfer (FRET). 
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FRET	  
Förster Resonance Energy Transfer (FRET) is a process of non-radiative energy 
transfer between two chromophores, the donor and the acceptor. A German 
scientist, Theodor Förster, was the first to describe the phenomenon back in the 
1940s (40). In FRET, the acceptor molecule can either be fluorescent or non-
fluorescent, with a spectral overlap of the donor and acceptor chromophores 
required (Fig 3). Another requirement for FRET is close proximity of the two 
chromophores, typically in the range of 15 to 60 Å. Moreover, the dipole-dipole 
angles of the donor and acceptor should not be perpendicular to each other (75). 
The theoretical intensity of FRET between a given donor-acceptor pair can be 
estimated by the Förster distance, R0, which represents the distance between the 
donor and acceptor, at which the energy transfer is 50% efficient (40,75). The 
Förster distance can be calculated by the following equation: 
 𝑅! = 0.211 𝜅!𝑛!!𝑄!𝐽 𝜆 !!/! 
 
where 𝜅! is a factor describing the dipole orientation (usually assumed to be 2/3), 
n is the refractive index of the medium (typically ¼ for aquetious solutions), 𝑄! is 
the quantum yield of the donor in the absence of the acceptor, and 𝐽 𝜆   is the 
spectral overlap of the donor-acceptor pair (75). 
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Figure 3. Schematic illustration of the overlapping spectra of the donor-emission 
and acceptor-absorption wavelengths. The overlapping spectra are in orange. Abs, 
absorbance; Em, emission. Modified with the permission from the publisher. (Valeur B, 
Berberan-Santos MN editors. Molecular Fluorescence: Principles and Applications. 
second ed.: Wiley-VCH Verlag GmbH & Co.; 2013, page 113.) 
 
Molecular processes behind the absorption and emission of light in FRET are 
illustrated in the Figure 4 Jablonski diagram. As the donor absorbs energy, it 
moves from the singlet ground state (S0) to the higher level of the first excited 
singlet state (S1), The molecule rapidly returns to the lowest energy level of S1 
(vibrational relaxation), and if in close-enough proximity to an appropriate 
acceptor, the donor transfers part of its excitation energy to the acceptor via 
dipole-dipole coupling (75,126). 
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Figure 4. Jablonski diagram illustrating energy states and transitions between 
donor and acceptor molecules. Horizontal arrows illustrate energy state transitions 
due to absorption or emission of photons. Wavy arrows illustrate vibrational relaxation. 
 
Time-­‐Resolved	  FRET	  
Biological samples such as serum are prone to autofluorescence, which limits the 
use of conventional fluorophores. Time-resolved detection of FRET efficiently 
minimizes the sample-derived autofluorescence. Time-resolved FRET relies on 
two important properties of the donor fluorophore: long emission half-life and a 
large Stokes shift. Stokes shift is the gap between the maximum of the first 
absorption band and emission spectra of the same electronic transition, 
measured as wavelengths or frequency units. For example, in FRET, the donor 
absorbs a photon, enters an excited state and transfers its excitation energy to 
the acceptor. When the acceptor emits light at lower energy than the original 
absorption, the energy difference is called the Stokes shift (75). TR-FRET utilizes 
rare-earth elements, ones with exceptionally long emission half-lives in their 
cryptic or chelated forms, to enable time-resolved detection. These unique rare 
earth elements, such as europium (Eu) or terbium (Tb), are called lanthanides, 
and they typically serve as donors for acceptors such as Alexa Fluor or cyanine 
dyes such as Cy5. The correct term for the light emitted by lanthanides would be 
luminescence or photoluminescence, however, this light is commonly referred to 
as time-resolved fluorescence (46). This thesis uses the term “fluorescence”. 
The applicability of lanthanide chelates as “reporters” (also known as “labels”) for 
time-resolved fluorometry (TRF) was already attracting interest in the 1970s 
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(118), with much progress and research on this topic resulting 
(28,51,54,74,94,119). An ideal reporter should fulfill certain requirements such as 
small size, stability, hydrophilic nature, and high luminescent intensity. To fulfil 
these requirements, lanthanide ions must be combined with an organic 
chromophore (chelate). The chelate absorbs the excitation energy and transfers it 
to the lanthanide ion, which then moves into an excited state. The chelate 
structures include a reactive group used for coupling the reporter to 
biomolecules, and this also shields the lanthanide ion from the quenching effects 
of water (51,55,112). Figure 5 illustrates the structure of an Eu chelate (W1024) 
with isothiocyanate activation chemistry. Luminescent Eu chelates are commonly 
used as donors for TR-FRET-based applications. The spectral properties of Eu 
chelates make them good candidates as donors, since they exhibit a large 
Stokes shift with no overlap between the excitation (at around 340) and emission 
(at around 615 nm) wavelengths. In addition, the emission wavelength of Eu is 
above the autofluorescence originating from biological samples (usually 400–600 
nm) (44,54).  
 
 
 
 
 
 
 
Figure 5. The structure of an Eu chelate (W1024) with isothiocyanate activation 
chemistry. Modified with permission of BN products & Services Ab Oy. 
 
FRET-­‐based	  applications	  	  
FRET has been widely applied in biomedical research in proximity-based assays. 
Here the term “proximity” refers to the characteristics of FRET, because FRET 
requires the close proximity of the donor and acceptor for sufficient energy 
transfer. Examples of FRET-based applications include those studying protein-
protein interactions, DNA-hybridization, ligand-receptor binding, and antigen-
antibody binding (7,12,59,62,69,82,90,135,136,138).   
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Many of the applications studying antigen-antibody binding by FRET rely on time-
resolved detection. Four basic configurations for such assays are commonly used 
depending on whether the assay is performed on a solid-phase (heterogeneous, 
multistep) or a solution-phase format (homogeneous, separation-free), and 
whether the assay is competitive or non-competitive (45). One of the first 
homogeneous immunoassays utilizing TR-FRET was established in the 1980s for 
the detection of thyroxin (53). FRET as a detection method also enables 
multiplexing by use of a variety of distinct label pairs (71,72,135). Such 
applications have been reported with either distinct donors (116) or a variety of 
acceptors in the same dual-label assay (71). Quantum dots (QDs) offer an 
interesting tool for applications utilizing FRET for multiplexing. These are small 
nanocrystals with unique photophysical properties, and can serve as FRET 
donors or acceptors. The high extinction coefficients, narrow emission bands, 
broad excitation and absorption spectra, and enhanced photostability make them 
superior to traditional organic fluorophores. The fluorescence emission of QDs is 
size-dependent, which makes them tunable. In addition, QDs appear particularly 
efficient in sensitivity, and due to their broad emission spectra, they also enable 
multiplexing at even up to six distinct wavelengths (18,59,96,140). 
.     
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AIMS	  OF	  THIS	  STUDY	  
 
Aims of the present study were to explore the possibilities of TR-FRET for rapid 
serodiagnosis of infectious diseases. 
 
More specifically the aims were 
 
• to determine whether a bivalent IgG molecule can act as a 
“FRET bridge” 
• to determine the applicability of TR-FRET in homogeneous 
immunoassays 
• to evaluate the clinical performance of these homogenous TR-
FRET assays with hantavirus disease as the model 
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MATERIALS	  AND	  METHODS	  
 
Ethics statement 
All serum samples for this study were originally sent to Helsinki University Central 
Hospital Laboratory Diagnostics (HUSLAB, Department of Virology and 
immunology), and studied under research permits § 32, 14 June 2013, and 
553/E6/2001. 
Antigens and antibodies 
Antigens and antibodies are indicated in Table 3, in which PAb refers to 
polyclonal antibody and MAb to monoclonal antibody. PUUV-N represents an 
immunodominant antigen in PUUV infection, and for our experiments was 
expressed by use of the baculovirus system in insect cells (129). VP1u-GST is an 
antigen including the unique region of human parvovirus B19 minor capsid 
protein (VP1), expressed in E. coli as a GST-fusion protein (89). The antigenic 
region we targeted was the GST.  
Fab fragments from an anti-streptavidin (anti-SA) MAb, when generated and 
purified, served as a control in the FRET-bridge assay. Briefly, the MAb was 
fragmented with papain, and the reaction was carried out at 37°C for 4 h. 
Thereafter, the papain was inactivated with iodoacetamide. To remove any 
remaining intact IgGs and to separate the cleavage products (Fab and Fc), we 
used Gammabind™ Plus Sepharose™ (GE Healthcare), and the resulting 
supernatant containing the Fab fragments was concentrated with Amicon Ultra 10 
kDa centrifugal filter units (Millipore). A more detailed protocol for this procedure 
appears elsewhere (109). 
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Table 3. Antigens and antibodies for the experiments, including suppliers.  
 
Product name Supplier  
PUUV-N Reagena Ltd (129) 
Anti-PUUV N MAb (clone 3H9) Åke Lundkvist, University of Uppsala (84) 
Anti-PUUV N MAb (clone 1C12) Åke Lundkvist, University of Uppsala (84) 
PierceTM Recombinant protein L Thermo Fischer Scientific 
Europium chelate-labeled streptavidin PerkinElmer  
Alexa Fluor 647-labeled streptavidin  Thermo Fischer Scientific 
Anti-SA MAb (mouse IgG2, clone 
S3E11) 
Thermo Fischer Scientific 
Anti-SA PAb Abcam Ltd 
Anti-SA PAb Springbioscience Inc 
Anti-GST MAb Abcam Ltd 
VP1u-GST An in-house product (89) 
 
Fluorophore-labeling reactions 
The antigens PUUV-N and VP1u-GST, and the protein L were labeled with 
Europium-chelate (Eu) by the QuickAIIAssay Eu-chelate protein-labeling kit (BN 
Products & Services Oy). The VP1u-GST, the protein L, and the anti-PUUV 
MAbs were labeled by the Alexa Fluor 647 (AF647) protein-labeling kit 
(Invitrogen). All labeling reactions were according to manufacturers´ instructions.  
Clinical samples 
All serum samples were originally sent to HUSLAB for analysis of their PUUV 
antibodies. While setting up the LFRET assay, we used a panel of 58 archival 
samples, and the assay performance was further evaluated by 153 coded 
samples, which we examined blindly. The parameters of the CFRET were 
optimized by use of 128 retrospective samples, and further evaluated by 201 
coded samples. 
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TR-FRET assays 
FRET	  bridge	  	  
The protocol, as described (109), was as follows: the labeled antigens and the 
antibody were combined at a reaction volume of 20 µl and dispensed by pipette 
onto a microwell plate. The results were thereafter detected with a Wallac Victor2 
fluorometer (PerkinElmer) by excitation at 320 nm followed by a delay of 70 µs 
before recording the fluorescence. The fluorescent counts were recorded for 100 
µs with 615 nm (Eu) and 665 nm (AF647) emission filters and normalized 
following the equation: AF647N = AF647–k*Eu, in which AF647N means 
normalized AF647 fluorescent counts, AF647 means unnormalized A647 counts 
(at 655 nm), k means Eu emission at 665 nm/Eu emission at 615 nm, and Eu 
means Eu fluorescent counts (at 615 nm). The assay principle is illustrated in 
Figure 6.  
 
Figure 6. The FRET-bridge assay principle. A variety of molecule combinations form 
after the combination of the reaction components. FRET signal forms when donor-
labeled and acceptor-labeled antigens are simultaneously bound to an IgG. 
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LFRET	  
Initially the protocol was this: labeled protein L was mixed with the antibody, 
followed by 15 min incubation at 37°C, and thereafter mixed with labeled antigen 
at a reaction volume of 20 µl. This mixture was dispensed onto a microwell plate, 
and the results were detected with a Wallac Victor2 fluorometer (PerkinElmer). 
The protocol was slightly modified when adapted to clinical samples. The serum 
samples were IgG-depleted by diluting them 1/10 in GullSORB (Meridian 
Bioscience Inc.), followed by centrifugation at a relative centrifugal force (RCF) of 
16 000 for 10 s. The remaining supernatant was further diluted to obtain a final 
dilution (on plate) of 1/100. Two sample preparations were studied: one with and 
one without IgG depletion. At first, labeled protein L was combined with the 
antigen, and 15 µl of the mixture was dispensed onto a microwell plate followed 
by addition of 5 µl of serum dilution. The results were detectable with a Wallac 
Victor2 fluorometer after 30 min at +37 °C. The measurement parameters were 
the same as described above for FRET bridge. More details are available (56,57) 
and the assay principle is illustrated in Figure 7.  
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Figure 7. The LFRET assay principle. After combining the reaction components 
(labeled antigen, labeled protein L, and antibodies), a variety of molecule combinations 
form. FRET signal forms, when acceptor-labeled protein L and donor-labeled antigen are 
bound by the same Fab-arm of an Ig. This principle is exemplified by an IgG, although 
similar FRET-active complexes also form with other antibodies, such as IgM. 
	  
CFRET	  
The protocol was in brief: the antigen and serum sample were combined and 
dispensed onto a microwell plate followed by 10-min incubation at RT. Labeled 
anti-PUUV-N monoclonal antibody (3H9) was added to the wells followed by a 
second incubation period of 15 min at RT. The final reaction volume was 20 µl. 
Finally, the results were detected with a Wallac Victor2 fluorometer. For each 
sample, two preparations were examined: one with and one without IgG 
depletion. IgG depletion was performed as described above for LFRET, and the 
samples were further diluted to obtain 1/50 dilution on the plate. Measurement 
parameters were the same as for LFRET and FRET bridge. More details of the 
protocol are available (58). The assay principle is in Figure 8.  
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Figure 8. The assay principle of CFRET. After the combination of the reaction 
components (labeled antigen, labeled MAb, and serum antibodies), a variety of molecule 
combinations form. The lack of FRET signal indicates a positive sample, since the serum 
antibodies compete for antigen binding, thus preventing any FRET-signal formation 
between competitive acceptor-labeled MAb and donor-labeled antigen. This principle is 
exemplified by an IgG. 
 
Reference	  methods	  
Reference methods used to evaluate the performances of CFRET and LFRET 
immunoassays in PUUV diagnostics were an IgM-capture enzyme immunoassay, 
an IgG IFA, and an IgM IFA. The IgM-capture enzyme immunoassay and the IgG 
IFA (49,67) are accredited (SFS-EN ISO/IEC 17025 and SFS-EN ISO 15189; 
Finnish Standards Association) and used in diagnostics in HUSLAB. All of the 
reference tests are manufactured in-house, and the assay times range from 3 to 
4 hours. The antigen for the IgM-capture enzyme immunoassay was 
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manufactured similarly to the one we used in LFRET- and CFRET assays (129). 
For more details and the protocol for PUUV IgM IFA see Hepojoki et al. (58). 
 
Statistics 
The statistical tool for analyses in the LFRET assay was IBM SPSS software 
version 21. The SAS 9.3 program served as the tool for calculating the Spearman 
correlations for the CFRET.  
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RESULTS	  	  
 
Introduction     
The four studies of this thesis project, which explored rapid antibody detection by 
FRET-based applications, developed three distinct approaches, two of which 
were also successfully applied in clinical virology. Study I introduced a concept 
utilizing FRET-pair-forming fluorophore-labeled antigens for antibody detection in 
a homogeneous assay format. Simultaneous binding of the antigens to an 
antibody induced a FRET signal. We designated this assay the “FRET bridge.” 
Study II and Study III dealt with another FRET-based homogeneous 
immunoassay, designated “LFRET,” which utilized fluorophore-labeled protein L 
and fluorophore-labeled antigen to detect antibodies. Here, a FRET signal was 
detectable when both labeled molecules, protein L and antigen, were bound to 
the same Fab arm of an Ig. Study II introduced the proof of concept using SA as 
an antigen, whereas in Study III, the LFRET was applied for diagnosis of acute 
PUUV infection.  
In Study IV, a competitive FRET-based immunoassay detected antibodies by 
fluorophore-labeled MAb in combination with a fluorophore-labeled antigen. The 
labeled MAb competes with serum antibodies in binding to the antigen, which in 
the case of a positive sample resulted in FRET-signal inhibition. This assay was 
designated “CFRET”, and also here the first clinical application was developed for 
diagnosis of PUUV infection. 
 
FRET bridge  
Study I examined the possibility of detecting antibodies in a homogeneous assay 
format by FRET-pair-forming fluorophore-labeled antigens. Initially, the 
functionality of the FRET-bridge assay was examined by a series of cross-
titration assays. With both antigens (donor-labeled and acceptor-labeled 
streptavidins) at 8 nM, the specific antibodies (PAb and MAb) induced TR-FRET 
signals, whereas the control produced only background fluorescence. The signals 
recorded with the PAb increased dose-dependently, whereas with the MAb, a 
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peak was observable at a concentration of 17 nM, after which the signals began 
to decrease. Also with the PAb, at lower antigen concentrations than 8 nM, a 
similar peak was observable as was with the MAb (Figure 9). Fab fragments of 
the anti-SA MAb served as a control, which showed no FRET activity above the 
recorded background signals. 
 
 
Figure 9. Antibody-antigen titration. The left graph represents results from the anti-SA 
PAb, while the right graph represents those from the anti-SA MAb. The antigen 
concentrations were from 0.5 nM to 8 nM. Y-axis: normalized response counts (FRET 
signal); X-axis: antibody concentration. 
 
To examine the sizes of the TR-FRET-inducing molecular complexes, we 
separated them by sucrose-gradient ultracentrifugation and analyzed the 
fractions. By this, we sought to study whether TR-FRET signals derive from one 
IgG plus two antigens, the original hypothesis. Anti-SA MAb and PAb in 
combination with the tetravalent SA were subjected to separate examinations, 
both yielding similar results, indicating that TR-FRET activity derives from 
molecular complexes of various sizes. With MAb, most of the FRET activity 
derived from high-density fractions corresponding to a relative molecular mass 
(Mr) of 500 to >1000 kDa. Examination of distinct combinations of antibody and 
antigen showed the most suitable to be a 1:1 ratio, since in this case virtually no 
antibodies migrating without the antigen were detectable. A minor proportion of 
TR-FRET signal was observable in lower-density fractions corresponding to an 
Mr of ∼300 kDa (Figure 10). As to the suitability of a monovalent antigen, we 
examined VP1u-GST for the FRET-bridge assay. The combination of 
fluorophore-labeled VP1u-GSTs and anti-GST failed to induce positive FRET 
signals.  
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Figure 10. Analysis of immune complexes in density-gradient ultracentrifugation. 
The left graph represents results with the anti-SA MAb, whereas the right graph 
represents results with the anti-SA PAb (Abcam). Black line: FRET response; dark gray 
line: relative antibody concentration. Light gray line: estimated molecular weight (Y-axis) 
for each sucrose concentration (X-axis). The second Y-axis represents a relative scale 
for both antibody and FRET signal. 
 
LFRET 
Study II explored the proof of concept for another homogeneous immunoassay. 
Here, the antibodies were detected by a fluorophore-labeled antigen and a 
fluorophore-labeled immunoglobulin-binding molecule called protein L. Also here, 
the suitable assay conditions were examined by cross-titration, followed by 
examination of the fluorophore labels´ best positioning. The most suitable signal-
to-noise (S/N) ratios resulted from the acceptor label in the protein L and the 
donor in the antigen. The optimization experiments were performed by using two 
antigens in parallel: a tetravalent SA and a monovalent VP1u-GST. To examine 
whether FRET signals truly originate from a single Fab arm, anti-SA Fab 
fragments cleaved from an anti-SA MAb were combined with protein L and SA. 
When compared to intact MAb, similar, although slightly weaker, dose-dependent 
FRET signals resulted.  
PUUV nucleocapsid protein served as the first viral antigen in the LFRET assay. 
Study III established the proof of concept for detecting human PUUV antibodies 
with LFRET with a retrospective sample panel consisting of 58 serum samples 
characterized as 21 with acute infection, 17 as past infection, and 20 as negative. 
Based on results with these sera, the threshold for positivity was set at signal 
level 3-fold the background, which corresponds to the average + 5.79 times the 
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standard deviation (SD) of signals induced by the negative samples. Of the 21 
acute-infection (IgG+ IgM+) samples, 20 induced positive TR-FRET signals, 
whereas of the 17 past-infection (IgG+ IgM−) samples, only 10 were identifiable as 
positive. None of the seronegative (IgG− IgM−) samples induced TR-FRET 
signals ≥3-fold the background signals.  
Next came evaluation of the clinical performance of the assay with a prospective 
sample panel using coded (blind) samples. Altogether 211 (prospective + 
retrospective panels) samples were examined. Of the 61 acute-infection 59 
(97%), and of the 27 past-infection samples 14 (52%), induced LFRET-positive 
signals, but false-positive results in the 103 seronegative samples numbered only 
7. After IgG depletion, 58 of the acute-infection samples, 95.1%, induced positive 
signals, while all of the past-infection and seronegative samples were identifiable 
as negative (Table 4). 
 
Table 4.  LFRET in a total of 211 samples.  
 
  Acute (IgG+/IgM+) Past (IgG+/IgM-) Negative (IgG-/IgM-) 
Test result (n) LFRET Reference LFRET Reference LFRET Reference 
Acute (61) 58 61 0 0 0 0 
Past (27) 1 0 14 27 0 0 
Neg (123) 2 0 13 0 123 123 
Total (211) 61 61 27 27 123 123 
 
Pearson correlation of the reference ELISA IgM absorbance values (at 1:200 
dilution) with the S/N ratios of the 40 IgG-depleted coded acute-phase samples 
showed a correlation coefficient of 0.19 (P = 0.24, i.e., nonsignificant). However, 
after ignoring one outlier with an exceptional signal-to-noise ratio (24), the 
Pearson correlation (r) was 0.35, which is statistically significant (P = 0.0276). 
 
CFRET 
In selection of the competing PUUV-N antibodies, performances were compared 
of two MAbs, 3H9 and 1C12, in the CFRET assay. Whereas both MAbs were 
inhibited by sera of PUUV-seropositive individuals (both acute- and past-
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infection), the MAb 3H9 was inhibited proportionately more than was MAb 1C12. 
Hence, the following experiments were performed only with MAb 3H9.  
While setting up the assay parameters, we observed that all of the 21 acute-
phase samples, examined with and without IgG depletion, induced relative TR-
FRET inhibition >20%. Of the 19 past-infection samples, 15 induced relative TR-
FRET inhibition >20% without IgG depletion, whereas with IgG depletion, all of 
the samples exhibited inhibition values <20%. All 21 seronegative samples 
induced <20% inhibition values regardless of IgG depletion.  
Based on these data, we set the threshold for positivity at 20% relative TR-FRET 
inhibition, which corresponds to the mean + 3.6 SDs of the inhibition values of 
negative samples without GullSORB treatment and the mean + 3.8 SDs of the 
inhibition values of negative samples with GullSORB treatment. Diagnosis of 
acute-phase PUUV infection was achieved by comparing results from serum 
samples with and without IgG depletion. Samples inducing >20% relative TR-
FRET inhibition with or without IgG depletion represented acute-phase infection, 
whereas past infection samples induced inhibition values >20% only when IgG 
was present. Those samples that induced inhibition values <20% regardless of 
IgG depletion were considered negative. In total, we analyzed 128 retrospective 
samples. 
In the prospective study, 201 coded samples underwent analysis. By comparing 
the inhibition values with and without IgG depletion, all of the 40 acute-phase 
samples were identified, whereas of the 14 past-infection samples, only 12 
induced positive signals with IgG present and none induced signals without IgG. 
Of the 142 seronegative samples, 2 induced positive signals; one was identified 
as acute and the other as past infection. Of a total of 329 samples tested, the 
CFRET assay identified acute PUUV infection with 100% sensitivity and 99.1% 
specificity, and the respective values for past-infection samples were 78.5% and 
99.7%. Results of the retrospective and prospective sample panels are 
summarized in Table 5.  
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Table 5.  Prospective and retrospective sample panels. CFRET results obtained from 
the 329 samples compared by reference methods. Modified with the permission of the 
American Society for Microbiology, from Hepojoki et al., “Competitive Homogeneous 
Immunoassay for Rapid Serodiagnosis of Hantavirus Disease,” J Clin Microbiol 
;53:2292-2297 2015. 
                                                                                                                                                                                                                                                                                                                             
  Acute (IgG+/IgM+) Past (IgG+/IgM-) Negative (IgG-/IgM-) 
Sample type (n) CFRET Reference CFRET Reference CFRET Reference 
Acute (101) 101 101 1 0 1 0 
Past (42) 0 0 33 42 1 0 
Neg (186) 0 0 8 0 184 186 
Total (329) 101 101 42 42 186 186 
 
Comparison of the sensitivities of CFRET and reference tests involved 
examination of randomly chosen samples representing 10 acute and 10 past 
infections in all assays (CFRET, IgG IFA, IgM ELISA, and IgM IFA). Results were 
that the highest IgM titer from the CFRET was 3,200, whereas for ELISA and IgM 
IFA the respective values were 25,000 and 2,560. The highest IgG titer that 
CFRET recognized was 200, while for the IgG IFA, it was 5,120 (Table 6). 
Comparison of IgG or IgM titers of the selected sera to the CFRET titers yielded 
poor correlations. When IgG and IgM IFA titers were summed (in 2-logarithmic 
scale), however, a significant correlation (Spearman's correlation coefficient [r] = 
0.62; P = 0.0036) resulted with the CFRET titer. We also compared the 
performances of CFRET and the LFRET by analyzing 131 (60 acute-infection, 26 
past-infection, and 45 seronegative) samples with both assays. The CFRET 
recognized 100% of acute-infection and 73% of past-infection samples, whereas 
the respective values with LFRET were 95% and 54%. All seronegative samples 
were identifiable with both assays. 
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Table 6. Comparison of assay sensitivities. Highest antibody titers indicated for each 
assay. Samples 1-10: acute infection; samples 11-20: past infection. Modified with the 
permission of the American Society for Microbiology, from Hepojoki et al., “Competitive 
Homogeneous Immunoassay for Rapid Serodiagnosis of Hantavirus Disease,” J Clin 
Microbiol ;53:2292-2297 2015. 
 
Samples IgG IFA IgM IFA IFAs combined ELISA 
CFRET  
with IgG 
CFRET 
without IgG 
1 1280 80 1360 200 800 800 
2 5120 320 5440 5000 800 800 
3 320 640 960 5000 200 200 
4 2560 80 2640 1000 50 50 
5 160 5* 165 5* 200 200 
6 5120 80 5200 1000 3200 3200 
7 40 2560 2600 25000 200 200 
8 5120 320 5440 5000 800 800 
9 640 1280 1920 25000 800 800 
10 5120 1280 6400 25000 200 800 
11 160 <10 160 <10 50 <10 
12 80 <10 80 <10 50 <10 
13 640 <10 640 <10 200 <10 
14 160 <10 160 <10 50 <10 
15 80 <10 80 <10 50 <10 
16 320 <10 320 <10 200 <10 
17 2560 <10 2560 <10 50 <10 
18 1280 <10 1280 <10 200 <10 
19 320 <10 320 <10 50 <10 
20 320 <10 320 <10 50 <10 
 
* This individual sample showed diagnostically low IgG avidity, despite discordantly below-cut-off 
levels of IgM antibodies to N by an EIA test.  
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DISCUSSION	  
 
This thesis presents three TR-FRET-based approaches for antibody detection. All 
are based on donor-labeled and acceptor-labeled components, which, when in 
close proximity, produce a FRET signal. In addition, all assays function in a 
homogeneous format.  
The FRET-bridge (I) assay was optimized by means of a model antigen, 
streptavidin (SA). We examined the molecular determinants behind the assay 
principle, and observed that the multivalency of SA seems to play an important 
role in FRET signal induction, since most of the FRET activity derived from large-
sized immunocomplexes. During application of LFRET (II and III) and CFRET (IV) 
for clinical diagnostics, PUUV served as the model pathogen. Both assays 
diagnosed acute PUUV infection with excellent specificity and very good 
sensitivity. 
 
FRET bridge 
The idea behind FRET bridging is based on two antigens binding to the same 
antibody. Antigens are separately labeled with specific fluorophores, which form a 
FRET pair. If these antigens are added to a solution containing their specific 
antibodies, they may bind to the same antibody, thus allowing FRET-signal 
formation.  
The antigen, SA, used while setting up this assay, is a tetravalent molecule; this 
means that, in theory, it is able to bind four identical IgG molecules. In the case of 
PAb (or serum antibodies), numerous antibodies can bind to SA, limited primarily 
by steric conditions, since unlike MAbs, which are a mixture of identical 
antibodies with the same epitope-specificity, PAbs and serum antibodies are a 
mixture of antibodies with distinct epitope specificities. This means that a PAb 
mixture (or serum antibodies) may contain numerous binding sites to a given 
antigen. In theory, to test the original FRET-bridge idea of a single IgG binding 
two antigens, one would actually need a monovalent antigen and a monoclonal 
antibody. However, since serum always contain a variety of antibodies with 
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distinct specificities, it is probable that even a monovalent antigen combined with 
serum samples would induce formation of FRET-active immunocomplexes.   
For both, monoclonal and polyclonal anti-SA antibodies, combining them with 
their labeled antigens induced FRET signals. With both antigens at 8 nM, the 
PAb induced dose-dependent FRET signals, while with the Mab, the signals 
increased dose-dependently only until a certain concentration. This is most likely 
explained by the prozone effect, which manifests in the excess of antibody in 
relation to the antigens, since more antibodies exist with only one bound antigen, 
and fewer antibodies with FRET activity. This was more evident with the MAb, 
since the concentration of the specific antibody in PAb is lower than it is in MAb 
(I, Fig. 3). 
We compared the performance of a PAb and a MAb in the assay, and observed 
that using a PAb produced much higher TR-FRET signals than did using the 
MAb.  We also studied the mechanism behind these results by fractionating the 
reagent components in a density gradient; we observed that the TR-FRET 
signals originated from molecular complexes of various sizes. Use of PAb seems 
to favor the formation of bulky immune complexes via non-covalent cross-linking 
of antigen molecules. Also with the MAb, most of the signals derived from 
immunocomplexes >700 kDa, corresponding to, for example, three IgG 
molecules (ca. 450 kDa) and four antigen molecules (ca. 250 kDa). Some FRET 
activity was also induced from fractions containing immunocomplexes 
corresponding to one IgG and two antigens in size. These results suggest that 
the FRET-bridge assay would greatly benefit from a multivalent antigen. Such an 
antigen could simultaneously bind several antibodies, and taking into account the 
bivalent nature of antibodies, they could also bind more than just one antigen. 
This would enable the formation of highly FRET-active immunocomplexes, in 
which several antigen-FRET pairs could form, when in close enough proximity. 
Performance of the FRET-bridge assay we also studied by use of a monovalent 
(or bivalent) antigen, GST-VP1u (53 kDa), in combination with an anti-GST MAb 
(II). This antigen was produced as monovalent, but because GST has a tendency 
to form dimers, bivalent forms are also possible (38). The GST-VP1u was 
originally produced for other purposes, but as it is close to SA in size, we 
hypothesized that it would also suit our experiments. However, no FRET activity 
occurred in these experiments (II, Fig. 8), supporting the finding that only a 
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multivalent antigen may induce proper FRET signals in the FRET-bridge assay. It 
is also possible that the degree of labeling (DOL) or positioning of the labels in 
the GST-VP1u was sub-optimal. 
Liu et al. (82) introduced a homogenous immunoassay for anti-BSA detection 
based on two-photon excitation similar to the FRET bridge. Although the 
detection technologies in two-photon excitation and TR-FRET differ, the assays 
resemble each other, since the polyclonal anti-BSA was detectable with the BSA 
antigens carrying distinct labels. Their results are in line with ours with SA and 
anti-SA, albeit the molecular properties of BSA differ from those of SA. At the 
concentrations that they used, BSA exists in monomeric forms (80), implying that 
the FRET-bridge assay could also function with monomeric antigens, even 
though the two techniques are not directly comparable. It is nevertheless possible 
that in their assay, as well, some sorts of immunocomplexes were formed that 
induce higher fluorescence signals than would only one IgG plus two antigens.  
Two-photon excitation-based POC assays are available also for infectious 
diseases, ones such as the mariPOC® assays developed by ArcDia International 
Ltd. These assays employ microspheres, which bind immunocomplexes formed 
by microbial antigens, a capture antibody, and fluorescent antibodies on their 
surfaces. Two-photon excitation serves as the detection method to 
homogeneously measure the fluorescence from individual microspheres, which 
corresponds to the amount of the analyte. The sensitivities and specificities of the 
mariPOC® resp assay, one that detects eight respiratory viruses, are a 
respective 85.4% and 99.2%; 84.6% of the positive results are identifiable in 20 
min (107). Unlike FRET bridge and the assay introduced by Liu et al., methods 
that detect antibodies, the mariPOC® assays detect microbial antigens, making 
these assays not directly comparable, for example, in terms of sensitivity. 
To further develop the FRET-bridge concept for infectious disease diagnostics, 
one would need to produce several microbial antigens in multivalent forms to 
examine their suitability for this assay format. Tailored recombinant antigens that 
would have several binding sites for antigens, such as the tetravalent SA, could 
enable the formation of highly FRET-active immunocomplexes. One challenge is 
the fluorophore labeling, since the labels attach randomly to free (and suitable) 
amino acids. Suitable binding sites depend on the labeling chemistry, but most 
often reactions target free amines available in the side-chains of lysines 
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(sometimes also N-terminus). More selective labeling can be achieved through 
use of thiol-reactive chemistries that target free thiol groups of cysteine residues. 
This means that in order for one to succeed in labeling the antigen, the labels 
should incorporate into amino acids that do not locate in immunologically 
important epitopes; moreover, the DOL (the number of label molecules per target 
molecule) should be optimal. For example, if the antigen is over-labeled, the spill-
over of the donor label into the acceptor channel becomes too high, and thus the 
specific signal diminishes. Finding the most optimal conditions for each antigen 
requires that the labeling reactions be optimized for both donor and acceptor. The 
inefficiency of the FRET-bridge assay is in part also due to the fact that in 
addition to binding FRET-pair-forming antigens, the antibodies can bind two 
acceptor-labeled or two donor-labeled antigens. This reduces the number of 
antibodies taking part in FRET signal formation.  
 
LFRET  
The second homogeneous immunoassay introduced (II, III) is based on a labeled 
immunoglobulin-binding molecule called protein L and a labeled antigen. Since 
FRET efficiency is dependent on the distance between the interacting donor and 
acceptor molecules, in an ideal assay the binding sites for both fluorophores are 
located in the Fab arm of the Ig molecule. As each IgG contains two Fab arms, 
two FRET pairs are possible within one IgG. In this assay, protein L and antigen 
were labeled separately with either a donor or an acceptor fluorophore, and 
functioned as a FRET pair. If these components bind to the same Fab arm of an 
Ig, a FRET signal forms in an assay time of 30 minutes.  
In the preliminary experiments, the highest S/N ratios appeared when protein L 
carried the acceptor fluorophore, and the antigen carried the donor (II, Fig. 3). 
This is most likely because an increase in the concentration of the acceptor label 
does not cause an increase in the background signal that is as large as when the 
increase occurs in the concentration of the donor label, due to the spill-over of the 
donor into the acceptor channel. Since only a fraction of the IgGs in human sera 
will be specific to a given antigen, it is beneficial to use the protein L in excess to 
saturate the binding to Ig molecules in the sample. Hence, we decided to 
continue the experiments with donor in the antigen and acceptor in the protein L.  
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Here, as well, SA served as the test antigen. The S/N ratios recorded were even 
higher than those with the FRET bridge. Several factors can contribute to this 
higher S/N ratio. The smaller distance between the interacting FRET pairs in 
LFRET enables a more efficient energy transfer, and each IgG molecule can also 
form two FRET pairs.  In addition, in LFRET both antigens binding to an IgG can 
form a FRET pair, as opposed to FRET bridge, in which an IgG can also form 
“homo-pairs” composed of two donors or acceptors, neither of which is FRET 
active.  
To show that the FRET signals indeed originate from the same Fab arm of an Ig, 
and originate not only between the two Fab arms, which is also possible, we used 
anti-SA Fab fragments prepared from an anti-SA MAb. A mixture containing the 
anti-SA Fab fragments combined with the labeled protein L and SA was able to 
induce similar dose-dependent FRET signals as an intact MAb, albeit at 
somewhat lower intensity. This is most likely due to the bivalent nature of an 
antibody, since one MAb can form two FRET pairs. In theory, FRET in an intact 
MAb may also occur between the two Fab arms, due to the flexibility of the Ig 
hinge region (13,108,120). Moreover, the procedure for creating the Fab 
fragments may have caused structural damage that affects the antigen binding.  
The nucleocapsid protein (N) of PUUV served as the first viral antigen in the 
LFRET assay (III). Puumala hantavirus induces a strong humoral IgM and IgG 
antibody response against the structural proteins (67), specifically the N protein, 
in the acute phase of infection, whereas in the past-infection phase, IgM 
response is absent. After optimization of the assay component concentrations, 
serum dilutions, and incubation time, we recorded FRET signals from both acute-
infection and past-infection samples. The signals recorded with acute-phase 
samples were in general higher than those with past infection (III, Fig. 2).  
To study the role of IgM in FRET-signal formation, we depleted all samples of 
IgG. Since IgM is present only in the acute phase of infection, those samples 
positive before IgG depletion but not afterwards represented old immunity, 
whereas those samples positive before and after IgG depletion represented acute 
infection. The higher signals induced by the acute-phase samples is most likely 
due to the role of IgM, since in those samples both types of immunoglobulins 
participate in FRET-signal formation. In addition, IgM usually exhibits a 
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pentameric form, which means that several FRET pairs can form within one IgM 
as compared to IgG, which at maximum forms two FRET pairs. 
The signal intensities recorded from individual samples varied within both 
cohorts: the acute- and the past-infection samples. This may reflect variation in 
antibody clonality.  The relation of antibodies with κ (protein-L binding) light chain 
to those with λ  light chain varies among individuals; human antibodies carry 
roughly two-thirds of κ , and one-third of λ  light chain(68). We furthermore 
examined—using acute-phase samples after IgG depletion—whether the FRET 
signals would correlate with reference IgM ELISA absorbance values. To our 
surprise, only a weak (r = 0.35), yet statistically significant (P = 0.0276), 
correlation appeared. One explanation for this could be the individual variability 
among antibodies and their light-chain types.  
We analyzed 211 serum samples originally sent to HUSLAB for suspicion of 
PUUV infection. The panel consisted of 61 acute-, 27 past-infection, and 123 
seronegative samples, and IFA (IgG) and IgM capture EIA served as reference 
methods. The panel included retrospective samples as well as prospective 
samples that we examined blindly. This assay was optimized by use of the 
retrospective samples, and was further evaluated (blind) using the prospective 
samples. After IgG depletion, all of the past-infection and seronegative samples 
were identified as negative, while among the 61 acute-phase samples, 58 
induced FRET signals.  
To conclude, with the LFRET assay, acute PUUV infection can be diagnosed at 
100% specificity and 95.1% sensitivity. The excellent performance of this assay 
in diagnosing acute hantavirus disease indicates that this approach could be 
applicable also to other important human pathogens. The assay format could be 
suitable for diagnosis of other disease types as well, such as allergies and 
autoimmunity. This is something well worth exploring. 
 
CFRET 
The third approach, CFRET, is based on competition between a fluorophore-
labeled MAb and serum antibodies. In this assay (IV), a fluorophore-labeled 
antigen and a fluorophore-labeled MAb form a FRET pair. If the serum contains 
antibodies with the same specificity as the MAb, they compete for antigen 
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binding, resulting in a decrease in the FRET signal. A FRET signal indicates, on 
the other hand, that the sample lacks the corresponding antibodies. Originally, 
McGiven et al. introduced this assay format for veterinary diagnostics (91). Their 
assay was developed for detection of anti-Brucella antibodies in ruminant serum 
samples. With slight modifications, we adapted the idea to human diagnostics, 
using PUUV as a model. The main differences between the assay of McGiven et 
al. and CFRET were the donor- and the acceptor labels. 
To optimize the assay for the detection of PUUV antibodies, two anti-PUUV-N 
MAbs targeting distinct epitopes, the 3H9 and 1C12, served in the preliminary 
experiments in parallel. While both of the MAbs were inhibited by PUUV-
seropositive samples, the results differed markedly. Most of the PUUV-positive 
sera, both acute- and past-infection, inhibited 3H9 more efficiently; hence we 
chose this antibody for future experiments (IV, Fig. 2). These results could be 
explained by the distinct binding affinities of each antibody, 1C12 being reactive 
with a conserved linear epitope shared between all hantaviruses, and 3H9 being 
a weaker binder detecting a species-specific epitope in a variable loop of 
hantavirus N and being consequently easier to compete with. What is also 
possible is that in individuals, antibody responses against the epitope that 3H9 
targets are more common than that of 1C12. 
This assay was optimized in terms of the assay component concentrations, 
serum dilutions, and incubation time by use of a retrospective sample panel, and 
was further evaluated using prospective (blind) samples. PUUV IgG IFA, IgM 
ELISA, and IgM IFA served as reference tests. In total, we examined 329 
samples consisting of 101 acute-, 42 past-infection-, and 186 seronegative 
samples. Preliminary experiments show the MAb binding to be inhibited more 
efficiently by acute-phase samples. Here, as well, IgG depletion enabled the 
diagnosis of acute PUUV infection, that is, by the presence of PUUV-specific IgM 
antibodies. Within the 30-minute assay time, acute PUUV infection was 
identifiable with 99.1% specificity and 100% sensitivity, whereas the respective 
values for past-infection samples were 99.7% and 78.5%. These diagnostic 
performances were close to those of McGiven et al. (91), whose homogeneous 
TR-FRET immunoassay for anti-bacterial antibodies was both 100% specific and 
sensitive. The study of McGiven and colleagues of the competitive TR-FRET 
immunoassay indicates that the CFRET assay format could also function well in 
diagnosis of human bacterial infections. The CFRET assay was optimized for 
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diagnosing acute infection (IgM detection), but also recognized past-infection 
sera, albeit at lower sensitivity. To increase its sensitivity for identifying the state 
of immunization, the assay would require further optimization. Combination of 
another antigen and its MAb may function more efficiently with past-infection 
samples. 
Comparison of the sensitivities and detection limits of CFRET and those of the 
reference tests (IgG IFA, IgM ELISA, and IgM IFA) showed lower sensitivity for 
CFRET in detecting both IgG and IgM than shown by the IgG IFA and IgM ELISA 
reference tests. CFRET performance was, however, more sensitive than that of 
the reference IgM IFA. The highest IgG titer that CFRET recognized was 200, 
while for the IgG-IFA it was 5,120. The corresponding titer of IgM by CFRET was 
3,200, whereas for ELISA and IgM IFA the values were respectively 25,000 and 
2,560. One explanation for this may be that enzyme-based assays in general are 
more sensitive because the signal is amplified by the enzymatic reaction.  
We also studied correlations between the recorded inhibition values and the 
respective IgM or IgG titers, but no correlation was apparent. However, when 
summing up the IgM- and IgG-IFA titers, a significant correlation (r = 0.62) 
emerged for the CFRET results, which possibly reflects the ability of CFRET to 
detect both antibody classes. The performances of CFRET and LFRET were also 
compared by analyzing 131 samples of serum. With this sample panel, the 
CFRET assay proved somewhat more sensitive (100%) than the LFRET (95%) in 
diagnosing acute PUUV infection, but the specificities of both assays reached 
100%.  
In terms of assay workflow, the LFRET is more straightforward, since all assay 
components are supplied at once. Compared to CFRET, the LFRET is also more 
robust in assay setup, since the protein L is supplied at a saturating 
concentration, and only the antigen concentration requires optimization, whereas 
in CFRET, the concentrations of antibody and antigen are nonsaturating. The IgG 
depletion included for both assays takes only 15 seconds of extra time, and does 
not much complicate sample handling. The only extra requirements for the 
depletion prestep are a table centrifuge and the GullSORB reagent. 
Based on its excellent sensitivity and specificity in hantavirus diagnostics, the 
CFRET may become widely applicable in diagnosis of other human pathogens as 
well. The ability to target specific epitopes would seem beneficial in distinguishing 
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highly cross-reactive species, such as the flaviviruses. Moreover, considering 
experimental research and veterinary diagnostics, this assay principle offers a 
new tool for screening of viral antibodies among animals lacking suitable 
secondary antibodies.  
 
TR-FRET as a detection method in infectious-disease 
diagnosis 
The FRET-based immunoassays introduced in this thesis offer a simple workflow 
and a rapid assay time of 15 to 30 minutes. The two applications, LFRET and 
CFRET, which we successfully applied in diagnosis of hantavirus disease, 
performed with high specificities and sensitivities, both closely approaching those 
obtained with the reference tests. The main benefits of the LFRET and CFRET 
immunoassays compared to those of conventional multistep assays are the lack 
of separation steps and reduced reagent consumption. These not only reduce 
assay time, but also reagent costs. Of note, the reaction volume of both assays, 
LFRET and CFRET, is only 20 µl. In addition, the hands-on time of the staff is 
reduced, and the results appear more rapidly. With the LFRET, what is in theory 
possible is that individual samples may exhibit in their antibodies amounts of λ 
light chain that are too low. This could affect assay sensitivity.  
The possible challenge for CFRET when applied to other antigens could involve 
finding a suitable epitope. For CFRET to function, the requirement is that the 
epitope against which the MAb is targeted should be such that all individuals 
having had the disease would have antibodies against it. However, it is probable 
that even if less than 100% of the individuals have antibodies against that specific 
epitope, they will have antibodies that bind so closely to the epitope that 
competition between antibodies and MAb is possible. 
One main benefit of using TR-FRET as a detection method, rather than traditional 
enzyme-based assays, is that fairly high signal-to-noise ratios can result without 
any additional washing steps. In addition, the platform can easily enable 
automated high-throughput screening. In terms of sensitivity, enzyme-based 
applications are often superior to those based on FRET. This is not only due to 
the signal amplification of enzyme-based assays, but other concerns also affect 
the sensitivity of FRET, and specifically homogeneous FRET assays. The 
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heterogenic assay format, which is often involved in enzyme-based assays, 
enables the washing of disturbing agents that possibly hinder the formation of 
specific signal. The homogeneous FRET assays are wash-free, which makes 
them rapid and simple, but also prone to disturbance by other biomolecules 
present in the sample other than the analytes. The spillover of the donor-label to 
the acceptor channel also affects sensitivity, but normalization of the FRET 
signals diminishes this effect.  
Regarding assay time and hands-on time, the FRET-based assays were superior 
to the multistep reference assays we used in this study. The assay times of IFA 
and ELISA range from 3 to 4 hours, including several separation steps. As to the 
aspect of sensitivity, it is probable that the LFRET and CFRET assays perform 
well with pathogens that raise high antibody responses, such as PUUV (67). 
Despite the limitations of FRET regarding sensitivity, both LFRET and CFRET 
performed well in diagnosis of acute PUUV infection, with sensitivities ranging 
from 95 to 100%, and specificities from 99 to 100%. Based on reports regarding 
the accuracy of available RDTs or POC assays for infectious diseases, most of 
which rely on antigen detection, these numbers are excellent (15,79,103,107). 
Since the accuracy of the LFRET and CFRET assays in terms of sensitivity and 
specificity is almost as good, both should be optimized and tested in parallel for 
new potential antigens to see which one performs better. 
Other issues also need consideration when applying FRET as the detection 
method. One critical step when setting up a FRET-based immunoassay is the 
fluorophore-labeling of the antigen (or other assay components). Not only is it 
important that while labeling the antigen, the immunologically important epitopes 
must remain intact; moreover, the DOL requires optimization. Here, the amino 
acid sequence of the antigen plays an important role, since the labeling reagents 
most commonly react with free amine groups. The labeling reactions for the Eu 
chelate used isothiocyanate, and the Alexa Fluor® used N-hydroxysuccinimide 
(NHS) ester, both of which target amines. Depending on the number of reactive 
groups and their location in respect to the critical epitopes, the outcome of the 
labeling reaction varies. This is something needing to be tested and optimized, 
since every molecule exhibits a unique amino acid profile. One possibility worth 
examining would be the expression of fluorescent tags, or linkers that would 
enable specific targeting of chromophores without any need for chemical labeling 
(133,134). The suitability of other donor-acceptor pairs should also be examined 
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to learn whether FRET efficiency between the donor and acceptor can be further 
increased.  
In addition, the size of the antigen plays a role in FRET efficiency. The ideal 
diameter of the antigen would allow the distance between the two chromophores 
to be minimal. Thus, either reducing or enlarging antigen diameter would 
negatively affect the distance between a given FRET pair and subsequently the 
signals obtained. PUUV-N is a 50 kDa protein which exhibits a diameter of 
approximately 5 nm (34). In the natural trimeric form of PUUV-N (93), the 
diameter grows to approximately 15 nm. Even if the antigen seems to function 
very well in the LFRET and CFRET assays, one could imagine achieving better 
FRET efficiency with a slightly smaller protein. Depending on the location of the 
labels, and the orientation of the bound antigens in relation to the FRET pair, the 
optimal antigen size is difficult to foretell, and requires physical examination.  
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CONCLUDING	  REMARKS	  AND	  PROSPECTS	  
 
This study was conducted to provide new insights into rapid serodiagnostics. This 
involved introduction of three approaches for rapid antibody detection, two of 
which, the LFRET and CFRET, were applied in clinical diagnosis. Both assays 
performed with high specificity and sensitivity in diagnosing acute hantavirus 
disease, and the next stage would be the application of these assays for 
diagnosis of other human diseases. Interesting viral pathogens include dengue 
viruses and tick-borne encephalitis virus. In addition to viral infections, the assays 
could also function in diagnosis of bacterial infections. Specifically Mycoplasma 
pneumoniae and the Borrelia burgdorferi sensu lato would be interesting targets 
to examine. Furthermore, the suitability of the rapid FRET assays for screening 
vaccine coverage against certain infections such as tetanus and rabies needs 
study.  
Both assays, LFRET and CFRET, are versatile in that they are not limited only to 
detection of IgG or IgM. The suitability of these assays should therefore be 
examined for other disease conditions as well, such as allergies and autoimmune 
diseases, by optimizing the assay for detection of IgE or IgA. Their applicability to 
other sample material in addition to serum, such as plasma, urea, saliva, and 
blood, also deserves examination. 
FRET as a detection method enables multiplexing. This would certainly add more 
value to the LFRET and CFRET assays, and needs study. Moreover, optimizing 
the performance of a portable FRET reader for these TR-FRET assays would 
surely prove valuable. At the moment, the suitability of such portable devices is 
under evaluation for the LFRET and CFRET.  
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